You just read:

High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinical Oncology

News provided by

Cell Therapeutics, Inc.

Feb 23, 2011, 01:30 ET